U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07905547) titled 'A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis' on Oct. 23.
Brief Summary: This study will describe safety of dupilumab in adult participants with atopic dermatitis. It will also look at the improvement of atopic dermatitis signs and symptoms in these participants.
The maximum study duration would be 32 weeks which includes the below:
* Up to 28 days of screening period in which the doctor will assess if the participant can be recruited in this study
* Treatment duration is 16 weeks
* Follow up period: during which the participant will be followed for 12 weeks to...